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Abstract The pharmacological management of disease
should involve consideration of the balance between the
beneﬁcial effects of treatment on outcome and the proba-
bility of adverse effects. The aim of this review is to
explore the risk of adverse drug reactions and drug–drug
interactions with treatments for postmenopausal osteopo-
rosis. We reviewed evidence for adverse reactions from
regulatory documents, randomized controlled trials, phar-
macovigilance surveys, and case series. Bisphosphonates
are associated with gastrointestinal effects, musculoskeletal
pain, and acute-phase reactions, as well as, very rarely,
atrial ﬁbrillation, atypical fracture, delayed fracture heal-
ing, osteonecrosis of the jaw, hypersensitivity reactions,
and renal impairment. Cutaneous effects and osteonecrosis
of the jaw are of concern for denosumab (both very rare),
though there are no pharmacovigilance data for this agent
yet. The selective estrogen receptor modulators are asso-
ciated with hot ﬂushes, leg cramps, and, very rarely,
venous thromboembolism and stroke. Strontium ranelate
has been linked to hypersensitivity reactions and venous
thromboembolism (both very rare) and teriparatide with
headache, nausea, dizziness, and limb pain. The solidity of
the evidence base depends on the frequency of the reaction,
and causality is not always easy to establish for the very
rare adverse reactions. Drug–drug interactions are rare.
Osteoporosis treatments are generally safe and well toler-
ated, though they are associated with a few very rare
serious adverse reactions. While these are a cause for
concern, the risk should be weighed against the beneﬁts of
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The management of osteoporosis is a major priority for
public health. The disease affects about one-third of women
over the age of 50 years, with a combined lifetime risk of
hip, forearm, or vertebral fracture of around 50%, on a par
with the risk associated with cardiovascular disease [1]. The
total direct costs in Europe were estimated at €31.7 billion
in 2000 and are expected to nearly double by 2050 due to
demographic changes in the population [2]. Effective and
safe treatments are clearly essential to reduce this burden.
Fortunately, there is currently a wide range of osteo-
porosis treatments, which reduce the risk for vertebral
fracture from 40 to 75% and, in some cases, nonvertebral
fractures by about 20% and hip fractures up to 40% [3].
Like any disease, the pharmacological management of
patients with osteoporosis should always involve consid-
eration of the balance between the risk of adverse drug
reactions and beneﬁcial effects in terms of reduction in the
risk of outcome. For osteoporosis, the outcome is vertebral
and nonvertebral fracture, which is associated with sig-
niﬁcant levels of morbidity and disability and, in the case
of vertebral and hip fracture, an increase in mortality.
Treatment decisions should be made to attain the maximum
reduction in risk of fracture with the minimum occurrence
of adverse reactions. On the whole, osteoporosis treatments
are remarkably well tolerated, though pharmacovigilance
and case studies have highlighted some rare serious
adverse drug reactions, which deserve further investigation.
The Working Group of the European Society for Clinical
and Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO) has focused on adverse reactions and drug–drug
interactions in the management of women with osteoporo-
sis. This review was prepared following these discussions.
An adverse drug reaction is deﬁned as an unintended
harmful or unpleasant response to a medicinal product,
which predicts hazard for future administration and war-
rants prevention or speciﬁc treatment, alteration of dosage,
or discontinuation [4, 5]. In general medicine, adverse drug
reactions are far more common than many physicians sup-
pose [5]. In one prospective observational analysis of nearly
20,000 hospital admissions, 6.5% of patients had some form
of adverse drug reaction, mainly due to aspirin, diuretics,
warfarin, and nonsteroidal anti-inﬂammatory drugs [6]. The
overall fatality in that analysis was 0.15%. Despite this,
many of the reactions are preventable through proper sur-
veillance and education of physicians and patients.
In this review, we examine the evidence for adverse
drug reactions with the following osteoporosis treatments:
bisphosphonates (alendronate, risedronate, ibandronate,
and zoledronic acid), denosumab, selective estrogen
receptor modulators (SERMs, raloxifene and bazedoxif-
ene), strontium ranelate, teriparatide, and PTH(1–84). We
report the prevalence of side effects and adverse reactions
according to the deﬁnitions used by the European Medi-
cines Agency (EMA): common (C1/100, \1/10), uncom-
mon (C1/1,000,\1/100), rare (C1/10,000,\1/1,000), and
very rare (\1/10,000).
Accurate interpretation of the risk of adverse reactions
and drug–drug interactions is difﬁcult due to the variety of
R. Rizzoli
Division of Bone Disease, Department of Rehabilitation
and Geriatrics, Geneva University Hospitals and
Faculty of Medicine, Geneva, Switzerland
J.-Y. Reginster (&)
Department of Public Health and Health Economics,
University of Lie `ge, Lie `ge, Belgium
e-mail: jyreginster@ulg.ac.be
S. Boonen
Leuven University Center for Metabolic Bone Disease
and Division of Geriatric Medicine, Katholieke
Universiteit Leuven, Leuven, Belgium
G. Bre ´art
INSERM U953, Ho ˆpital Tenon, Paris, France
A. Diez-Perez
Department of Internal Medicine, Autonomous
University of Barcelona, Hospital del Mar, Barcelona, Spain
D. Felsenberg
Center of Muscle and Bone Research, Charite ´–University
Medicine, Campus Benjamin Franklin, Berlin, Germany
J.-M. Kaufman
Department of Endocrinology and Unit for Osteoporosis
and Metabolic Bone Diseases, Ghent University Hospital,
Ghent, Belgium
J. A. Kanis
WHO Collaborating Centre for Metabolic Bone Diseases,
University of Shefﬁeld Medical School, Shefﬁeld, UK
C. Cooper
MRC Epidemiology Resource Centre, University
of Southampton, Southampton, UK
C. Cooper
NIHR Musculoskeletal Biomedical Research Unit, Department
of Musculoskeletal Science, University of Oxford, Oxford, UK
92 R. Rizzoli et al.: Adverse Reactions to Osteoporosis Treatments
123sources of information that provide varying levels of evi-
dence. The detection of an adverse reaction depends on the
relative frequency of the event and the temporality, the
mechanism of drug-induced toxicity, the number of
patients exposed to the drug, and the methods used to
detect the effect. There are three main sources of infor-
mation in addition to regulatory documents: randomized
controlled trials (RCTs), pharmacovigilance, and case
reports [4]. Table 1 summarizes the source of evidence for
the various adverse reactions with the osteoporosis treat-
ments described herein and the duration of postapproval
surveillance for each agent. Evidence from RCTs is
restricted to the most common adverse reactions due to the
small population size limited, at most, to a few thousand
patients, as well as the relatively short observation times.
On the other hand, rare side effects may not be detectable
by RCTs and only become evident in pharmacovigilance
surveys, which can cover hundreds of thousands of patients
over many treatment years. Case reports also constitute an
important source of information for the very rare events,
though causality is not always easy to establish. It should
be noted that the osteoporosis treatments that have been in
clinical use for longer are more likely to have reported
cases of rare adverse reactions than more recent arrivals to
the therapeutic armamentarium.
Adverse Reactions to Bisphosphonates
Bisphosphonates are stable derivatives of inorganic pyro-
phosphate and potent antiresorptive agents. They are
widely prescribed and highly effective at limiting bone loss
in osteoporosis. There have been a number of recent
reviews on the safety and tolerability of bisphosphonates in
osteoporosis [7–14] as well as in oncology, where higher
doses are applied alongside anticancer agents to prevent
skeletal complications and relieve bone pain [12, 15].
All of the bisphosphonates discussed below have proven
fracture efﬁcacy in phase III trials [3]. The phase III trials
for alendronate were carried out in the mid-1990s by the
Fracture Intervention Trial (FIT) investigators, who dem-
onstrated efﬁcacy against vertebral and nonvertebral frac-
ture, including hip [16, 17]. Alendronate was the ﬁrst oral
bisphosphonate and has 15 years of postapproval
Table 1 Source of evidence for adverse reactions to treatments in osteoporosis
Source of evidence Duration of postapproval experience in 2010
RCT Pharmacovigilance Case series
Bisphosphonates Alendronate, 15 years
Risedronate, 10 years
Ibandronate (oral), 5 years
Ibandronate (IV), 4 years





Atypical fracture/delayed fracture healing 44





Osteonecrosis of the jaw 44
Cancer 4








Strontium ranelate 8 years
Venous thromboembolism 4
Hypersensitivity reactions 44
Teriparatide or PTH(1–84) 8 years
Headache, nausea, dizziness, and limb pain 44
Osteosarcoma 44
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123surveillance data [18]. Similar fracture efﬁcacy was found
for oral risedronate, in the Vertebral Efﬁcacy with
Risedronate Therapy (VERT) trials [19, 20] and the Hip
Intervention Program (HIP) [21]. Risedronate was laun-
ched at the end of the 1990s, and there are now 10 years of
postapproval surveillance for this agent [22]. Ibandronate
has proven efﬁcacy against vertebral fracture, as shown by
the Oral Ibandronate Osteoporosis Vertebral Fracture Trial
(BONE) [23]; but pivotal trials have not shown nonverte-
bral or hip fracture risk reduction with this agent. Ibandr-
onate is prescribed both as a monthly oral formulation,
with 5 years of postapproval surveillance, and as a tri-
monthly intravenous (IV) formulation, with 4 years of
postapproval surveillance [24]. The most recently available
bisphosphonate is zoledronic acid, for which there is evi-
dence for the prevention of both vertebral and nonvertebral
fractures, including those of the hip, from the Health
Outcomes and Reduced Incidence with Zoledronic Acid
Once Yearly (HORIZON) trial [25]. Zoledronic acid has
been prescribed as a once-yearly IV formulation since 2007
[26], and there are 3 years of postapproval surveillance.
Gastrointestinal Effects
In their oral formulations, bisphosphonates may irritate the
upper gastrointestinal (GI) mucosa since it is exposed to
high concentrations at intake [27]. Proper adherence to
administration instructions can reduce frequency of GI
effects [27]. These include swallowing the drug with a
large glass of water and remaining in the upright position
for at least 30 min after intake (60 min for ibandronate).
Upper GI reactions are ‘‘common’’ with alendronate
[18]. They are the most frequently reported adverse reac-
tions with risedronate in drug monitoring, though the reg-
ulatory authorities do not cite an increased frequency of
upper GI reactions with risedronate [22] and pooled anal-
ysis of RCTs found no evidence for an increase in risk
compared with placebo [28]. Regarding ibandronate, GI
tolerability was initially thought to be of concern with the
high dosages necessary for monthly oral administration
(150 mg), but the investigators of the Monthly Oral
Ibandronate in Ladies (MOBILE) trial found no apparent
difference in GI adverse reactions between monthly and
daily formulations [29], with rates comparable to alendr-
onate (about 22%). Upper GI effects are less frequent with
weekly or monthly dosing than daily dosing for the same
agent. Oral alendronate, risedronate, and ibandronate tab-
lets also contain lactose, which causes abdominal dis-
comfort in some patients but is rarely a severe problem.
The prevalence of esophageal reactions with alendronate
is ‘‘common to rare’’ [18]. Two conﬂicting reports have
appeared on the association of the long-term use of oral
bisphosphonates(upto5 years)andincidenceofesophageal
cancer [30, 31], both performed in the UK General Practice
Research Database (GPRD). One of these reported a rate of
2/1,000 over 5 years (against a background rate of 1/1,000)
[30],whiletheotherreportednoassociationwithesophageal
orgastriccancerinusersvs. nonusers[31].Another analysis
of over 15,000 patients identiﬁed in RCTs or postapproval
surveys found rates of esophageal cancer similar to the
backgroundrates inthe population[32],with an incidence of
\1/1,000,000patient-yearsofexposure.TheFoodandDrug
Administration (FDA) currently recommends avoidance of
oral bisphosphonates in patients with Barrett’s esophagus, a
precursor of esophageal cancer, and has called for further
research on possible risk factors [33].
Musculoskeletal Pain
Chronic bone, joint, and muscle pain has been associated
with intake of both oral and IV bisphosphonates [34] and
was the subject of a warning from the FDA in 2008 [35].
The pathological basis for the reaction remains unclear,
though there may be a link with elevated parathyroid
hormone (PTH) levels [12]. Musculoskeletal pain is
‘‘common to rare’’ with alendronate [18] and ‘‘common’’
with zoledronic acid [26]. The FDA reports occurrences
with alendronate, ibandronate, risedronate, and zoledronic
acid, for which there was a (nonsigniﬁcant) difference vs.
placebo [35]. Musculoskeletal pain can occur at any time
during the course of treatment, though there may be some
overlap with acute-phase reactions (see below). It can be
difﬁcult to manage, especially if severe [7, 8, 10]. Stopping
treatment may give complete relief of symptoms, though
there are cases of slow or incomplete resolution [34].
Acute-Phase Reactions
Acute-phase reactions have been reported with alendro-
nate, ibandronate, and zoledronic acid [9, 10, 12] and are
characterized by low-grade fever, sometimes with rigors,
and inﬂuenza-type symptoms, such as fatigue, malaise,
headache, myalgia, arthralgia, and bone pain. They are
attributed to altered activation and proliferation of c-d T
cells [36]. Onset may occur within 3 days of drug admin-
istration. The reaction is transient and generally resolves
within 3 days [14].
These are rated as ‘‘rare’’ to ‘‘uncommon’’ by the EMA
[18, 24, 26]; they appear to be more frequent with the IV
bisphosphonates and are very rare following oral admin-
istration [37]. In the Dosing Intravenous Administration
(DIVA) study, ﬂu-like illness (33 symptoms) was reported
to occur with an incidence of 4.9% with IV ibandronate vs.
1.1% for oral ibandronate [38]. They were also more
common after the ﬁrst injection of ibandronate than after
subsequent administrations. Acute-phase symptoms have
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123also been recorded after infusion of zoledronic acid (31.6%
after ﬁrst infusion vs. 6.2% in the placebo group, less so
after second infusion) [25, 26]. Acute-phase reactions are
generally mild to moderate in intensity and are rarely the
cause of withdrawal in RCTs. They can be treated symp-
tomatically with paracetamol or other analgesics or anti-
pyretics. The likelihood of experiencing this reaction can
be reduced by administration of analgesics for a few days
just after dosing [10].
Atrial Fibrillation
Concern over the possibility that bisphosphonates could
induce atrial ﬁbrillation [39, 40] followed the observation
of a small but signiﬁcant increase in this event with
zoledronic acid in HORIZON when reported as serious
adverse events (50 events [1.3%] with zoledronic acid vs.
20 events [0.5%] with placebo, P\0.001) [25]. The
treatment–placebo difference was no longer signiﬁcant
when the events were analyzed separately as atrial ﬁbril-
lation or atrial ﬂutter events, sick sinus syndrome, or
arrhythmias, adjudicated or not. Similar ﬁndings were
reported for alendronate in a post hoc analysis of the FIT
trial [41], in which there was a trend toward signiﬁcance
for atrial ﬁbrillation (47 events [1.5%] with alendronate vs.
31 events [1.0%] with placebo, P = 0.07). Possible
mechanisms for the modiﬁcation of atrial conduction by
bisphosphonates include intracellular electrolyte homeo-
stasis and proinﬂammatory, proﬁbrotic, and antiangiogenic
effects [40].
Observational studies have failed to detect an increase in
atrial ﬁbrillation with any of the bisphosphonates [42, 43].
There is no RCT evidence that risedronate is associated
with atrial ﬁbrillation [44], and postapproval surveillance
indicates an incidence of \1/1,000,000 patient-years with
this agent. Similarly, there was no increase in atrial ﬁbril-
lation in any of the ibandronate trials. Finally, a recent
systematic review and meta-analysis concluded that,
though there are data linking bisphosphonate use to atrial
ﬁbrillation, the exact nature of the risk remains unclear
because of the heterogeneity of the evidence and the lack
of information on some of the agents [45]. In 2008, the
FDA concluded that no change in treatment should be
made with respect to atrial ﬁbrillation [34].
Atypical Subtrochanteric Fracture and Delayed
Fracture Healing
The occurrence of atypical subtrochanteric fracture and
delayed fracture healing with bisphosphonates has been the
subject of a separate ESCEO Working Group meeting and
review [46] and a report from a Task Force of the Amer-
ican Society for Bone and Mineral Research [47] and will
be discussed only brieﬂy here. Case reports draw attention
to an association between subtrochanteric fractures and
exposure to bisphosphonates, possibly related to long-term
suppression of bone turnover [48], as demonstrated by the
absence of tetracycline labeling [49]. Cortical bone appears
to be the most affected, and patients with thick cortices
may be more susceptible to an effect on fracture [48].
Further supporting results for the deterioration of bone
structural quality with long-term bisphosphonate use were
presented at the annual meeting of the American Academy
of Orthopedic Surgeons in March 2010 [50, 51].
There is no RCT evidence for an increase in the risk of
subtrochanteric fractures with any of the bisphosphonates
[52]. There have been case reports of atypical fracture or
delayed fracture healing with long-term alendronate
[18, 53–55], even though there are no quantitative differ-
ences in bone microarchitecture with alendronate [56].
There is also evidence from case series with risedronate
[54, 55], for which postapproval surveys indicate \1/
100,000 patient-years [57]. There are three cases of atyp-
ical subtrochanteric fracture with ibandronate [55], which
occurred after 4 months to 1 year of ibandronate treatment
preceded by 3–10 years of alendronate. There was no
delayed fracture healing in the HORIZON trial (3.2% with
zoledronic acid vs. 2.7% with placebo, nonsigniﬁcant) [58].
The evidence for a link between increased atypical
subtrochanteric fracture or delayed fracture healing and
long-term bisphosphonate therapy [46] generally comes
from retrospective case series with small numbers of
patients involved. The low frequency of atypical subtro-
chanteric fractures and the difﬁculties surrounding the
deﬁnition of patients at risk considerably complicate the
attribution of causality [52]. Current hypotheses include a
possible association of reduced bone turnover induced by
the bisphosphonate and other risk factors, such as younger
age at initiation or concomitant therapy with corticoste-
roids, proton pump inhibitors, or other antiresorptive
treatments [47, 52]. Further studies, including prospective
controlled studies, meta-analyses, and nested case-control
studies, are necessary to determine the role of other con-
comitant risk factors [46].
Osteonecrosis of the Jaw
Osteonecrosis of the jaw is the appearance of exposed bone
in the mandible, maxilla, or both that persists for at least
8 weeks in the absence of radiotherapy or jaw metastases.
The condition is known to affect patients receiving IV
bisphosphonate for metastatic disease [59]. Patients in
oncology generally receive much larger doses than those
with osteoporosis. Assessment of causality is very difﬁcult,
though there is a possible role of inﬂammation and infec-
tion [60, 61].
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phosphonate treatment for osteoporosis has already been
the subject of a separate ESCEO Working Group paper
[61]. Osteonecrosis of the jaw is very rare with oral bis-
phosphonates in the management of osteoporosis, and
current estimates of incidence stand at around 1/38,000
patient-years of treatment [61–64]. Data from the GPRD
and The Health Improvement Network (THIN) suggest that
the annual incidence of all osteonecrosis is 2 to 3/100,000,
independently of bisphosphonate use [65]. The lower doses
of bisphosphonates used in osteoporosis, in comparison
with oncology, appear to be safe [66].
There have been no cases of osteonecrosis of the jaw
reported with risedronate in RCTs, and the postapproval
reporting rate is\2/100,000 patient-years, with 434 reports
in which 30–35% of patients had taken the drug for
\1 year (S. Boonen, personal communication). There were
two cases of osteonecrosis of the jaw in the HORIZON
trial, one in the zoledronic acid group and one in the pla-
cebo group [67]. The rate in the zoledronic acid-treated
osteoporotic population is currently estimated at 0.9/
100,000 patient-years of treatment. For ibandronate, the
rate is 0.9/1,000,000 patients exposed in osteoporosis vs.
2.3/100,000 patients exposed in oncology (R. Schimmer,
personal communication).
Some strategies for prevention of osteonecrosis of the
jaw have been proposed in oncology, including good oral
hygiene, completion of dental work prior to initiation of
treatment, and discontinuation of treatment for 3 months in
the event that a dental procedure is necessary [61, 66]. Any
intervention at the jaw in patients using bisphosphonates
for osteoporosis should include antibiotic therapy for
3 weeks. Management of osteonecrosis of the jaw involves
treatment of secondary infections, analgesia, and surgical
removal of necrotic debris [63, 68].
Hypersensitivity Reactions
Cutaneous adverse reactions are the subject of a separate
ESCEO report [69]. Cases of Stevens-Johnson syndrome
and toxic epidermal necrolysis have been reported for all
the bisphosphonates [13, 69], though these remain very rare
(\1/10,000 patients). These reactions have a strong tem-
porality and appear within 5–10 days of initiation of
treatment. Unsurprisingly for a very rare reaction, there are
more case reports for the agents that have been in clinical
use for the longest. The prognosis is good if the reaction is
recognized early and managed appropriately [69].
Renal Safety
The use of IV bisphosphonates in oncology has been
associated with rare cases of deterioration of renal function
due to the high doses administered over a short period of
time [70]. Analysis of the HORIZON trial demonstrated
the renal safety of IV zoledronic acid in osteoporosis [70],
with no long-term change in renal function in terms of
creatinine clearance. There were transient rises in serum
creatinine in 1.8% of treated patients vs. 0.8% of the pla-
cebo group, but all cases were completely resolved. The
FDA reports 24 cases in postapproval (i.e., very rare),
while the EMA describes renal impairment as ‘‘uncom-
mon’’ and advises precaution in at-risk patients [26]. Fur-
ther support for the good renal safety of IV
bisphosphonates in osteoporosis comes from a pooled
analysis of the renal tolerability of ibandronate in four
RCTs. No relevant differences in parameters of renal tox-
icity were found between the IV formulation and oral
formulations (incidence of increase in serum creatinine
from baseline of C 0.5 mg/dl of about 0.4%). Regardless
of dose, creatinine clearance remained at baseline levels
and was comparable to placebo [71].
Adverse Reactions to Denosumab
The efﬁcacy of denosumab in the prevention of fracture in
postmenopausal osteoporosis was demonstrated vs. placebo
in the Fracture Reduction Evaluation of Denosumab in
Osteoporosis Every 6 Months (FREEDOM) trial [72].
Denosumab is a fully human monoclonal antibody against
the RANK ligand and a potent inhibitor of osteoclast-
mediated bone resorption. Denosumab was approved for
clinical use very recently, so the only evidence for safety
and adverse reactions in osteoporosis is based on phase III
studies [72, 73] and regulatory documents [74]. Case
reports with the agent are rare, and there are not yet any
pharmacovigilance data.
There were no signiﬁcant differences between denosu-
mab and placebo in terms of the total incidence of adverse
events in FREEDOM or in the Denosumab Hormone
Ablation Bone Loss Trial (HALT) [72, 73]. In FREEDOM,
adverse events occurring with an incidence of 2% or
greater and a signiﬁcant difference from placebo
(P B 0.05) were eczema and ﬂatulence [72]. Serious
adverse events occurring with an incidence of 0.1% or
greater and a signiﬁcant difference from placebo
(P B 0.01) included cellulitis and concussion.
Infections
Data from RCTs indicate a higher rate of serious infection
with denosumab than placebo (4.4% vs. 3.6%, respec-
tively) [74–76], including infection of the skin, the ear, the
GI tract, and the urinary tract. These can be related to
bacteria or unspeciﬁed pathogens. This is biologically
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lymphocytes, which, in the lymph nodes, are responsible
for recognition of foreign antigens [77]. RANKL inhibition
with denosumab may therefore play some role in arresting
these processes, though further research is necessary.
Infection of the urinary tract is rated as ‘‘common’’ by the
FDA [74].
The cutaneous effects observed in the denosumab RCTs
(eczema and cellulitis) were generally localized infections
in the lower extremities and often occurred in patients with
risk factors such as skin wounds or peripheral vascular and
venous stasis disorders. The clinical course generally
consisted of full recovery with no recurrence, though
cutaneous effects were linked to one death in FREEDOM
(one case of fatal cellulitis). These cutaneous effects do not
appear to be a local reaction to injection. It is too early to
determine causality, though an increase in cutaneous
effects with denosumab vs. placebo remained when data
fromFREEDOMandHALTwerecombined(D.Felsenberg,
personal communication). The rate can be estimated as
‘‘very rare’’ (\1/10,000 patients). The risk should be
monitored.
Osteonecrosis of the Jaw
Given the observations with the bisphosphonates, it might
be expected that a potent antiresorptive agent such as
denosumab could also pose a potential risk for osteone-
crosis of the jaw [78]. There were no cases of osteonecrosis
of the jaw in the phase III studies of denosumab in oste-
oporosis. There is one case report of osteonecrosis of the
jaw in a male patient receiving denosumab in a trial in
oncology [79]. Moreover, the reaction has been reported in
34 subjects receiving denosumab for the management of
metastatic disease [80]. The rate can be estimated at around
2/100, but the true risk is unknown and should be moni-
tored. It should be noted that in this comparative trial the
rate of occurrence of osteonecrosis of the jaw was 1.4% in
zoledronic acid-treated patients.
Cancer
Preregistration RCTs with denosumab indicate slightly
higher rates of malignancy in osteoporotic women (4.0%
with denosumab vs. 3.3% with placebo) [74], principally
cancer of the pancreas, the GI and reproductive tracts, and
the breast. Breast cancer was the most common adverse
event that led to discontinuation in clinical trials (0.5%
denosumab vs. 0.3% placebo). The mechanisms underlying
these processes remain unclear, particularly in the absence
of an appropriate animal model as denosumab is not active
in rodents. The rate can be estimated as ‘‘very rare,’’
though further monitoring is necessary. A postmarketing
survey of more than 4,500 women has been launched in
postmenopausal women receiving the agent for up to
10 years.
Adverse Reactions to SERMs
SERMs partially mimic the effect of estrogens on bone and
the cardiovascular system and have estrogen antagonist
properties in the endometrium and breast. The efﬁcacy of
the SERM raloxifene in the prevention of osteoporotic
fracture was extensively studied in the Multiple Outcomes
of Raloxifene Evaluation (MORE) [81] and Continuing
Outcomes Relevant to Evista (CORE) [82]. Its effects on
breast cancer and other outcomes were explored in the
Study of Tamoxifen and Raloxifene (STAR) [83] and the
Raloxifene Use for the Heart (RUTH) trial [84, 85].
Raloxifene was launched in the 1990s and has 13 years of
postapproval surveillance [86].
There are two newcomers to the class. The SERMs
bazedoxifene and lasofoxifene were registered by the EMA
in 2009, but only basedoxifene is currently available for
clinical use [87–89]. The efﬁcacy of bazedoxifene at pre-
venting osteoporotic fracture over 3 years has been inves-
tigated vs. placebo [90], and its endometrial, ovarian, and
breast safety proﬁles have been evaluated in an RCT in
postmenopausal osteoporotic women, also over 3 years
[91]. Lasofoxifene has been studied in the 5-year Post-
menopausal Evaluation and Risk Reduction with Laso-
foxifene (PEARL) trial, which reported efﬁcacy at
increasing bone mineral density and reducing radiographic
vertebral fracture [92, 93].
Hot Flushes and Leg Cramps
The most common adverse reactions of the SERMs are
linked to their vasomotor effects. The incidence of hot
ﬂushes and leg cramps was signiﬁcantly increased in the
raloxifene trials [94, 95]. The mechanisms behind these
phenomena are believed to be related to the competing
effect of the SERM on the relevant estrogen receptor. In a
pooled analysis of nearly 900 women participating in phase
III trials, the relative risk of hot ﬂushes has been estimated
as 1.32 vs. placebo [94], with no apparent impact on the
natural course of incident hot ﬂushes. Regarding tempo-
rality, an 8-year analysis indicated that the increase in risk
was greatest within the ﬁrst 6 months of initiation of
raloxifene [95]. While hot ﬂushes and leg cramps were
more common in those receiving raloxifene over 8 years
than placebo, this was almost entirely explained by the
increased incidence of hot ﬂushes with raloxifene in the
ﬁrst 5 years. This observation may be due to the with-
drawal of those with severe hot ﬂushes or leg cramps from
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effectively reduces the risk for hot ﬂushes. These effects
are noted as ‘‘very common’’ for hot ﬂushes and ‘‘com-
mon’’ for leg cramps for raloxifene by the EMA [86].
Similar rates of hot ﬂushes and leg cramps are reported for
bazedoxifene and lasofoxifene [87, 88, 90, 92, 96].
Venous Thromboembolism
Like hormone replacement therapy, treatment with SERMs
is associated with an increased risk for venous thrombo-
embolism, including deep vein thrombosis and pulmonary
embolism [97]. The frequency of venous thromboembo-
lism was increased in phase III trials with raloxifene, with a
relative risk of about 1.7 vs. placebo in the combined
analysis of MORE and CORE [85, 95, 98]. A large pro-
portion of cases (69%) had some contraindication to
raloxifene (e.g., immobilizationor hypercoagulability) [99].
Theincidencewasreducedinthelong-termtrialCORE[95],
though this may have been linked to discontinuation due to
these adverse reactions and because these events occurred at
the beginning of treatment. The EMA notes this adverse
reaction as ‘‘uncommon’’ with raloxifene [86].
There are fewer data for bazedoxifene and lasofoxifene.
There was a higher incidence of deep vein thrombosis in
the RCTs with bazedoxifene (0.7% with bazedoxifene
20 mg/day vs. 0.3% with placebo) [90, 96]. Venous
thromboembolic events constituted an adjudicated end
point in the PEARL trial [92], in which lasofoxifene more
than doubled the relative risk, though the absolute risk was
very small (2.9 venous thromboembolic events per 1,000
patient-years with lasofoxifene 0.5 mg/day vs. 1.4 events
with placebo and 0.7 pulmonary embolism events per
1,000 patient-years vs. 0.2 events with placebo) [92]. The
EMA reports deep vein thrombosis as ‘‘uncommon’’ for
both lasofoxifene and bazedoxifene [87, 88].
Cardiovascular Events and Stroke
An increase in fatal stroke with raloxifene was reported in
RUTH (hazard ratio = 1.49, 95% conﬁdence interval [CI]
1.00–2.24, with an absolute increase in risk of 0.7 per 1,000
patient-years) [85], though secondary analysis of the trial
indicated that the risk of stroke varied according to
smoking status [100]. Analysis of the MORE and CORE
data set has demonstrated that raloxifene has no signiﬁcant
beneﬁcial or harmful impact on cardiovascular events (i.e.,
coronary or cerebrovascular) [101]. This observation is
also supported by the results of the RUTH study, in which
participants were at higher cardiovascular risk [85] and in
which there was no signiﬁcant difference in total strokes or
death from any cause. Moreover, there is evidence from
animal experiments that high doses of raloxifene may be
associated with some neuroprotective effects [102]. In the
MORE study, higher doses of raloxifene (120 mg/day)
were associated with some improvement in the results of
cognitive tests [103]. Regarding the other SERMS, there
was a moderate, nonsigniﬁcant increase in fatal stroke with
lasofoxifene in the PEARL study [92] and no difference
from placebo for bazedoxifene in the 3-year phase III trial
[90, 96]. The EMA rates the incidence of stroke (arterial
thromboembolic disorders) as ‘‘very rare’’ [86].
Gynecological Safety
Raloxifene and bazedoxifene have no impact on endome-
trial thickness [96, 104]. There was no signiﬁcant differ-
ence in the incidence of uterine cancer, endometrial
hyperplasia, ovarian cancer, or postmenopausal bleeding
between raloxifene and placebo in the analysis of MORE
and CORE [95]. There was a greater incidence of uterine
polyps, though all of these were benign and not associated
with endometrial cancer. Uterine polyps were also more
common with lasofoxifene than placebo in the PEARL
study [92]. The rate of these events can be estimated as
‘‘very rare’’ (\1/10,000 patients).
Adverse Reactions to Strontium Ranelate
Strontium ranelate is an orally active agent which decrea-
ses bone resorption and increases bone formation markers,
with a net result of improved microarchitecture [105]. The
efﬁcacy of strontium ranelate in the prevention of vertebral
and nonvertebral fractures, including hip fracture in a
subgroup at risk of hip fracture, has been demonstrated in
postmenopausal osteoporotic women over 3 years in the
Spinal Osteoporosis Therapeutic intervention (SOTI) [106]
and up to 5 years in the Treatment of Peripheral Osteo-
porosis (TROPOS) trial [107]. There were no signiﬁcant
safety issues in either of these phase III trials. Strontium
ranelate has been in clinical use since 2004 and has 6 years
of postapproval surveillance.
Venous Thromboembolism
There was no increase in venous thromboembolism with
strontium ranelate in the SOTI and TROPOS populations.
However, when the two trial populations were pooled, the
annual incidence of venous thromboembolism over 5 years
was 0.9% with strontium ranelate vs. 0.6% with placebo
(relative risk = 1.4, 95% CI 1.0–2.0) [108]. While these
rates of venous thromboembolism are similar to those in
the age-matched general population [109–111], they
required further investigation. A retrospective study in the
GPRD database identiﬁed 11,546 untreated osteoporotic
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alendronate, 2,408 osteoporotic women treated with
strontium ranelate, and 115,009 nonosteoporotic women
[112]. The risk for venous thromboembolism in this
population-based sample was signiﬁcantly increased in
the untreated osteoporotic patients compared with their
nonosteoporotic counterparts (hazard ratio = 1.43, 95%
CI 1.10-1.86; P = 0.007, age-adjusted model). The
authors attributed this increase in risk to the reduced
mobility associated with osteoporosis. There was no
difference between the rates of venous thromboembolism
in untreated and treated osteoporotic patients, whatever
their treatment (strontium ranelate or alendronate). Sim-
ilar ﬁndings have been reported from two other obser-
vational studies, so the postmarketing data are reassuring
[113, 114].
Hypersensitivity Reactions
Strontium ranelate has been associated with rare cases of
the hypersensitivity drug reaction with eosinophilia and
systemic symptoms (DRESS). The incidence of this
adverse reaction is extremely low, estimated at 1/54,000
patient-years of treatment. This has been discussed in a
recent ESCEO Working Group review [69]. Early recog-
nition and proper management by stopping the agent are
mandatory and improve prognosis.
Adverse Reactions to Teriparatide or PTH(1–84)
Teriparatide, the 1–34 N-terminal fragment of human PTH,
has bone-forming properties [115]. It has been demon-
strated to effectively reduce vertebral and nonvertebral
fractures over 21 months in postmenopausal osteoporotic
women [116]. Its use is limited to 24 months of treatment
[115, 117]. Teriparatide has been in clinical use since 2002
and has 8 years of postapproval surveillance. PTH(1–84)
was approved for vertebral fracture prevention in 2006 and
is available in some countries [118].
Nervous System Disorders
In the placebo-controlled trials of teriparatide and
PTH(1–84), there were a number of minor adverse reac-
tions, including headache, nausea, and dizziness, which are
rated as ‘‘common’’ to ‘‘very common’’ by the EMA.
Teriparatide also appears to be associated with an increase
in limb pain [117], which is noted as ‘‘very common’’ by
the EMA. In a study exploring the efﬁcacy of combination
teriparatide and raloxifene in osteoporosis, muscle spasm
was the only adverse reaction reported to be related to
treatment with teriparatide [119].
Osteosarcoma
There were no cases of osteosarcoma in the RCTs with
teriparatide or PTH(1–84), though teriparatide has been
reported to induce osteosarcoma in experimental animals
[120, 121]. There is one case report of osteosarcoma with
teriparatide in a 70-year-old postmenopausal woman with a
complex medical history [122]. This reaction is rated as
extremely rare (1/100,000 patients) and should be consid-
ered against the background incidence in the general pop-
ulation, which is around 0.4/100,000 per year in a
population aged over 60 years [8, 122]. However, this has
led to an FDA warning [123], including a statement that
patients who have skeletal metastases, Paget disease, or
open epiphyses should not be prescribed teriparatide.
Drug–Drug Interactions in Osteoporosis
Drug–drug interactions are rare in the management of
osteoporosis and discussed only brieﬂy here. Coadminis-
tration of oral bisphosphonates and calcium or acid-sup-
pressant medication, or indeed any other oral medications
containing divalent cations, is known to interfere with
absorption of the bisphosphonate. Calcium supplementa-
tion should therefore be distanced from bisphosphonate
intake. An apparent increase in the risk of fracture has been
reported in individuals receiving acid-suppressant medi-
cation (proton pump inhibitors) but not with histamine H2-
receptor antagonists [124]. This increase in risk remained
in patients receiving acid-suppressant medication in com-
bination with bisphosphonates vs. bisphosphonate alone.
Given the nature of the risk, this issue requires further
exploration.
Caution is also recommended with oral bisphosphonates
and the concomitant use of agents that irritate the gastric
mucosa (e.g., nonsteroidal anti-inﬂammatory drugs) due to
the GI effects of the bisphosphonate. There does not appear
to be cause for concern over drug–drug interactions for
ibandronate [125]. Renal damage due to bisphosphonates
could be exacerbated by nonsteroidal anti-inﬂammatory
agents, aminoglycoside antibiotics, antiretroviral therapies,
or diuretics [126, 127]. Thus, care should be taken to
administer IV bisphosphonates to only fully hydrated
patients. Regarding zoledronic acid, renal function should
be monitored and drugs affecting cardiac arrhythmias
should be used with caution. One case of transient elevated
liver enzymes has been reported with zoledronic acid and
ibuprofen. There are not yet any reported drug–drug
interactions of concern for denosumab.
Cholestyramine and colestipol may also affect the
absorption and enterohepatic recycling of raloxifene.
Levothyroxine may decrease the absorption of the drug.
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ranelate. There are possible interactions with quinolones,
tetracycline antibiotics, and aluminum and magnesium
hydroxides; and the administration of strontium ranelate
should be separated from intake of dietary calcium by 2 h.
There is a possible interaction between teriparatide and
other treatments that affect serum calcium, though no
interaction has been detected with digoxin or thiazides.
Discussion and Conclusion
This review indicates that the most serious adverse reac-
tions are very rare in the management of postmenopausal
osteoporosis and that the osteoporosis treatments are gen-
erally free of serious drug–drug interactions. We have
reviewed the most commonly used osteoporosis treatments
in Europe as well as new agents in the ﬁeld.
Causality is notoriously difﬁcult to attribute for rare
adverse drug reactions, e.g., osteonecrosis of the jaw and
atypical subtrochanteric fracture [4, 5, 128]. Such decisions
are also fraught with interrater differences in opinion since
studies repeatedly show low agreement between experts
regarding causality when they assess the same case reports
[129]. Causality can only be deﬁnitively established if a
certain number of criteria are met: (1) a plausible tempo-
rality in relation to administration; (2) a reasonable
mechanism in view of the agent concerned; (3) a frequency
that differs from the background rate of the event in the
population; and (4) evidence from dechallenge and
rechallenge (though this is clearly not an option in the case
of life-threatening events). One example of the difﬁculties
in establishing causality in osteoporosis is osteosarcoma
with teriparatide, which appears to occur at rates similar to
the background rate in the elderly population. While the
best evidence for causality should ideally come from RCT










GI effects (oral formulations) Common (C1/100) ?? ?? ? ? ?
Musculoskeletal pain Common (C1/100) ?? - ? -
Acute-phase reactions (IV formulations) Common (C1/100) ?? ?? ? ? ?
Atrial ﬁbrillation Very rare (\1/10,000) -- - - -
Atypical fracture/delayed fracture healing Very rare (\1/10,000) ±- - ? ?
Osteonecrosis of the jaw Very rare (\1/10,000) -- - - ?
Hypersensitivity reactions Very rare (\1/10,000) ?? - ? -
Renal impairment Very rare (\1/10,000) ?? ? ? ?
Denosumab
Severe infection Common (C1/100) ?? - ? ?
Osteonecrosis of the jaw Very rare (\1/10,000) -- - - ?
Cancer Very rare (\1/10,000) -- - - -
SERMs
Hot ﬂushes Very common ([1/10) ?? ?? ? ? ?
Leg cramps Common (C1/100) ?? ? ? ?
Venous thromboembolism Uncommon (C1/1,000
to\1/100)
?? ? ? ?
Stroke Very rare (\1/10,000) -- - - -
Endometrial effects Very rare (\1/10,000) ?? ? ? ?
Strontium ranelate
Venous thromboembolism Very rare (\1/10,000) ?- - - -




Common (C1/100) ?? ? ? ?
Osteosarcoma Very rare (\1/10,000) -- - - ±
?? strong evidence, ? evidence, ± mixed evidence, - no evidence
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instance, there were only two reports of bisphosphonate-
related osteonecrosis of the jaw in RCTs, and one of those
was in the placebo group.
The monitoring of risk and pharmacovigilance are
therefore central features of any drug safety program.
Improvements in pharmacovigilance should increase the
knowledge of adverse reactions via intensive monitoring
and database studies (such as those performed on venous
thromboembolism and osteonecrosis of the jaw in the
GPRD) and the use of algorithms for assessing the proba-
bility of an adverse reaction [130, 131]. Indeed, postap-
proval studies are necessary to make objective decisions
regarding rare serious adverse reactions. As shown in
Table 1, the rare adverse reactions are generally only
reported in pharmacovigilance or as case series and often
only appear with widespread clinical use of the agent
concerned. Regarding case reports, the evidence base is
less solid, partly because they may be biased by opinions of
the reporter and partly because they do not necessarily give
an accurate assessment of the risk due to underreporting or
selective reporting [130].
Table 2 synthesizes and classiﬁes the adverse drug
reactions to osteoporosis treatments in terms of their
prevalence, the strength and consistency of the association,
dose–response and temporality, and biological plausibility
as reported in this review. For the sake of simplicity, we
have assumed class effects for the bisphosphonates and
SERMs. The more common adverse reactions, e.g., GI
effects with oral bisphosphonates and hot ﬂushes with
SERMs, are well documented and generally associated
with higher values for strength and consistency of the
association, dose–response, temporality, and biological
plausibility. On the other hand, the rarer adverse reactions
have no strong evidence on any of these points and yet are
serious enough to require further monitoring. For example,
osteonecrosis of the jaw and atypical subtrochanteric
fracture have been clearly documented as issues of concern
by regulatory authorities for the antiresorptive agents;
however, the low incidence of the reactions and the limited
capacity to explore it using conventional evidence criteria,
such as RCTs, make it difﬁcult to be categorical about the
association.
A good management strategy should always weigh the
risk of adverse reactions against the beneﬁts of treatment,
i.e., the prevention of osteoporotic fracture. We should
recall that all the osteoporosis treatments covered in this
review have proven efﬁcacy at reducing vertebral fracture
in women with postmenopausal osteoporosis, and some
have evidence for nonvertebral and hip fractures. It should
be noted that perhaps the biggest risk associated with
adverse drug reactions might be that a patient’s fear of an
adverse reaction would prevent him or her from taking the
osteoporosis medication in the appropriate manner, thereby
increasing the risk of fracture. In this context, great care
should be applied in the provision of information on
adverse drug reactions to patients, particularly in light of
studies that show that patients signiﬁcantly overestimate
the likelihood of an adverse reaction occurring [132, 133].
In conclusion, osteoporosis treatments are generally safe
and well tolerated. They are associated with a few very rare
serious adverse reactions, such as osteonecrosis of the jaw,
atypical fracture, and atrial ﬁbrillation. While these are
clearly a cause for concern and should be the subject of
further investigations and monitoring, the risk of these rare
events, which occur at a prevalence of less than 1 in 10,000
patients, should be weighed against the beneﬁts of treat-
ment itself, i.e., the prevention of osteoporotic fracture and
associated morbidity.
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